Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co. is organized around three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. Co.'s clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy. The ATNX stock yearly return is shown above.
The yearly return on the ATNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|